Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Brain Drug Firm Envoy Is Going To Takeda
by Michael McCoy
November 12, 2012
| A version of this story appeared in
Volume 90, Issue 46
Takeda Pharmaceutical has agreed to acquire Envoy Therapeutics for as much as $140 million, a sum that includes an up-front sum and progress-dependent preclinical milestone payments. Based in Jupiter, Fla., Envoy uses its bacTRAP technology to label and extract the protein-making components of cells. Takeda says the technology is especially powerful in tissues of the brain. Takeda first invested in Envoy in 2009. It plans to move most of the firm’s 21 employees to its San Diego R&D facility early next year.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter